Skip to main content
. 2011 Aug 10;6(8):e23092. doi: 10.1371/journal.pone.0023092

Figure 8. Differential vRNA analysis of SIVsmE660 and SIVmacC8 in plasma.

Figure 8

Plasma SIV RNA levels shown for superinfected vaccinates (B204/B209) and six protected vaccinates (B202, B203, B205, B206, B207, B208) using a SIVsmE660-specific viral RNA assay (panels A and B respectively), compared to unvaccinated naive challenge controls (panel C) with the same assay. Controls were eight naïve MCMs challenged with 10 MID50 of the SIVsmE660 stock (1/10,000 dilution of the original stock; B7, B8, B95, B96, B210–B213) or productively infected at the 1/100,000 dilution (B98). Levels of the vaccine virus SIVmacC8 are shown in panels D and E for superinfected and protected vaccinates respectively with the SIVmac251-specific qPCR assay [8]. Panel F shows no reactivity >50 SIV RNA copies/ml of the SIVmacC8-specific assay with unvaccinated challenge controls sampled at 14, 84 and 140 days post SIVsmE660 challenge.